Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
- Resource Type
- Article
- Authors
- Saha, Aditi; Jhaveri, Khushali; Sarfraz, Humaira; Chavez, Julio C
- Source
- Expert Opinion on Biological Therapy; September 2023, Vol. 23 Issue: 9 p869-876, 8p
- Subject
- Language
- ISSN
- 14712598; 17447682
ABSTRACTIntroductionTisagenlecleucel (tisa-cel) is an anti CD19 CAR-T therapy that has demonstrated clinical activity in R/R large B-cell lymphoma and R/R B-cell acute lymphoblastic leukemia. It showed particularly high efficacy in R/R follicular lymphoma (FL) with a manageable toxicity profile. The pivotal ELARA study in R/R FL confirmed these findings and led to the FDA approval of tisa-cel in R/R FL after two lines of systemic therapies.Areas coveredWe start with an introduction of FL and the current treatment landscape with emphasis on the R/R setting. We review the role of CAR-T in R/R FL with focus on currently available products. We describe the ELARA study at a high level to give a perspective of the patient population that was treated. Finally, we discuss aspects related to product selection and whether bispecific antibodies will challenge the role of CAR-T in FL given their similar efficacy.Expert opinionTisa-cel is a highly effective therapy for heavily pretreated R/R FL with a toxicity profile that is low grade and manageable. Durable remissions (including high-risk patients) are seen in the pivotal ELARA study. Clinicians should consider early referral of R/R FL patients for assessment and discussion.